File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Treatment outcome of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients using rituximab-based regimen

TitleTreatment outcome of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients using rituximab-based regimen
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 82-83, abstract no. P-0121 How to Cite?
AbstractPURPOSE/OBJECTIVE: Post-tranplant lymphoproliferative disorder (PTLD) has a higher incidence in children than adults due to higher rate of seronegativity against Epstein-Barr virus. We reviewed the treatment results of PTLD in paediatric liver transplant recipients. MATERIALS AND METHODS: Clinical data of consecutive cases of PTLD diagnosed in paediatric liver transplant recipients in Queen Mary Hospital between 1-Jan-1999 and 31-Dec-2011 were reviewed up to the date of 31-Dec-2012. RESULTS: Twelve cases of PTLD (5 males; 7 females) were diagnosed during the study period. The majority had congenital biliary atresia and underwent liver transplantation before two years of age. The median age of diagnosis was 2.3 years (range, 0.8 to 9.5 years) and the median duration from time of transplantation to diagnosis was 10 months (range, 2 to 64 months). The median follow up duration was 3.7 years (range, 0.01 to 11.2 years). The clinical presentation varied from chronic infectious mononucleosis to frank lymphoma involving nodal or extranodal sites such as the liver graft and gastrointestinal tract. The histologic types comprised of monomorphic B cell (DLBCL, n ? 4; Burkitt, n ? 1), polymorphic B cell (n ? 3), T cell (n ? 1) and IM-like (n ? 3) PTLD. All had elevated plasma EBV loads at diagnosis. Treatment consisted of 4 weekly doses of rituximab at 375 mg/m2/dose for IM-like and polymorphous PTLD and low dose chemotherapy (up to 6 cycles of COP) in addition to 4 doses of rituximab for monomorphic PTLD. The 5-year event-free survival and overall survival were 58.3% and 66.7%, respectively. Three cases died of aggressive disease before treatment (2 monomorphic and 1 polymorphic PTLD presenting as leukaemia) and the case of T cell PTLD died after disease relapse. CONCLUSIONS: Vigilant monitoring for development of PTLD in paediatric liver transplant recipients is indicated. Rituximab-based regimen offers an effective treatment strategy.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Poster Presentation in Poster Session - Lymphomas: abstract no. P-0121
Persistent Identifierhttp://hdl.handle.net/10722/193640
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorChiang, AKen_US
dc.contributor.authorCheuk, DKLen_US
dc.contributor.authorHa, SYen_US
dc.contributor.authorChan, GCen_US
dc.date.accessioned2014-01-20T05:12:16Z-
dc.date.available2014-01-20T05:12:16Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 82-83, abstract no. P-0121en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/193640-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionPoster Presentation in Poster Session - Lymphomas: abstract no. P-0121-
dc.description.abstractPURPOSE/OBJECTIVE: Post-tranplant lymphoproliferative disorder (PTLD) has a higher incidence in children than adults due to higher rate of seronegativity against Epstein-Barr virus. We reviewed the treatment results of PTLD in paediatric liver transplant recipients. MATERIALS AND METHODS: Clinical data of consecutive cases of PTLD diagnosed in paediatric liver transplant recipients in Queen Mary Hospital between 1-Jan-1999 and 31-Dec-2011 were reviewed up to the date of 31-Dec-2012. RESULTS: Twelve cases of PTLD (5 males; 7 females) were diagnosed during the study period. The majority had congenital biliary atresia and underwent liver transplantation before two years of age. The median age of diagnosis was 2.3 years (range, 0.8 to 9.5 years) and the median duration from time of transplantation to diagnosis was 10 months (range, 2 to 64 months). The median follow up duration was 3.7 years (range, 0.01 to 11.2 years). The clinical presentation varied from chronic infectious mononucleosis to frank lymphoma involving nodal or extranodal sites such as the liver graft and gastrointestinal tract. The histologic types comprised of monomorphic B cell (DLBCL, n ? 4; Burkitt, n ? 1), polymorphic B cell (n ? 3), T cell (n ? 1) and IM-like (n ? 3) PTLD. All had elevated plasma EBV loads at diagnosis. Treatment consisted of 4 weekly doses of rituximab at 375 mg/m2/dose for IM-like and polymorphous PTLD and low dose chemotherapy (up to 6 cycles of COP) in addition to 4 doses of rituximab for monomorphic PTLD. The 5-year event-free survival and overall survival were 58.3% and 66.7%, respectively. Three cases died of aggressive disease before treatment (2 monomorphic and 1 polymorphic PTLD presenting as leukaemia) and the case of T cell PTLD died after disease relapse. CONCLUSIONS: Vigilant monitoring for development of PTLD in paediatric liver transplant recipients is indicated. Rituximab-based regimen offers an effective treatment strategy.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleTreatment outcome of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients using rituximab-based regimenen_US
dc.typeConference_Paperen_US
dc.identifier.emailChiang, AK: chiangak@hku.hken_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hken_US
dc.identifier.emailHa, SY: syha@hku.hken_US
dc.identifier.emailChan, GC: gcfchan@hku.hken_US
dc.identifier.authorityChiang, AK=rp00403en_US
dc.identifier.authorityChan, GC=rp00431en_US
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros227219en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage82-
dc.identifier.epage83-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats